agilon health, inc.（AGL）财务数据AGLagilon health, inc.

Evaluating the bottom line, agilon health, inc. maintains a gross margin of 12.82%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 0.79%, while the net margin is 1.20%. These profitability ratios, combined with a Return on Equity (ROE) of -78.94%, provide a clear picture of how effectively AGL converts its operational activities into shareholder value.

In the context of the broader market, AGL competes directly with industry leaders such as AZTA and SNDA. With a market capitalization of $1.55B, it holds a significant position in the sector. When comparing efficiency, AGL's gross margin of 12.82% stands against AZTA's 44.89% and SNDA's 100.00%. Such benchmarking helps identify whether agilon health, inc. is trading at a premium or discount relative to its financial performance.

Agilon Health reported Q2 revenue of $1.49 billion, exceeding expectations and showing a year-over-year growth of 7.2%. Adjusted EPS reached $2.15, significantly above the analyst estimate of $0.27, indicating strong operational performance.